WO2014163622A1 - Multifunctional quinoline derivatives as anti-neurodegenerative agents - Google Patents
Multifunctional quinoline derivatives as anti-neurodegenerative agents Download PDFInfo
- Publication number
- WO2014163622A1 WO2014163622A1 PCT/US2013/034960 US2013034960W WO2014163622A1 WO 2014163622 A1 WO2014163622 A1 WO 2014163622A1 US 2013034960 W US2013034960 W US 2013034960W WO 2014163622 A1 WO2014163622 A1 WO 2014163622A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- hydrogen
- formula
- independently hydrogen
- undecan
- Prior art date
Links
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 title description 4
- 230000002555 anti-neurodegenerative effect Effects 0.000 title 1
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 102
- 229940002612 prodrug Drugs 0.000 claims abstract description 19
- 239000000651 prodrug Substances 0.000 claims abstract description 19
- 239000000203 mixture Substances 0.000 claims abstract description 17
- 150000003839 salts Chemical class 0.000 claims abstract description 14
- 230000004770 neurodegeneration Effects 0.000 claims abstract description 12
- 239000002207 metabolite Substances 0.000 claims abstract description 11
- 239000012453 solvate Substances 0.000 claims abstract description 11
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 9
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 8
- 239000003085 diluting agent Substances 0.000 claims abstract description 7
- 238000004519 manufacturing process Methods 0.000 claims abstract description 3
- -1 CHj Chemical group 0.000 claims description 144
- 229910052739 hydrogen Inorganic materials 0.000 claims description 133
- 239000001257 hydrogen Substances 0.000 claims description 131
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 75
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 46
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 44
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 41
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 21
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 21
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 20
- 125000000623 heterocyclic group Chemical group 0.000 claims description 20
- KJIOQYGWTQBHNH-UHFFFAOYSA-N undecanol Chemical compound CCCCCCCCCCCO KJIOQYGWTQBHNH-UHFFFAOYSA-N 0.000 claims description 19
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 18
- 125000000217 alkyl group Chemical group 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 201000010099 disease Diseases 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 17
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 14
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 13
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 11
- 229910052736 halogen Chemical group 0.000 claims description 10
- 150000002367 halogens Chemical group 0.000 claims description 10
- 125000002947 alkylene group Chemical group 0.000 claims description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 claims description 7
- 150000002148 esters Chemical class 0.000 claims description 7
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 7
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 claims description 7
- 208000006011 Stroke Diseases 0.000 claims description 6
- 239000000460 chlorine Substances 0.000 claims description 6
- 229910052731 fluorine Inorganic materials 0.000 claims description 6
- REIUXOLGHVXAEO-UHFFFAOYSA-N n-pentadecyl alcohol Natural products CCCCCCCCCCCCCCCO REIUXOLGHVXAEO-UHFFFAOYSA-N 0.000 claims description 6
- QXVGZSLDGKOPHF-UHFFFAOYSA-N pentadecan-1-ol Chemical compound [CH2]CCCCCCCCCCCCCCO QXVGZSLDGKOPHF-UHFFFAOYSA-N 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 5
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 5
- 208000026139 Memory disease Diseases 0.000 claims description 5
- 125000001246 bromo group Chemical group Br* 0.000 claims description 5
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 5
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 claims description 5
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 claims description 5
- 229910052744 lithium Inorganic materials 0.000 claims description 5
- 206010027175 memory impairment Diseases 0.000 claims description 5
- CDAWCLOXVUBKRW-UHFFFAOYSA-N 2-aminophenol Chemical compound NC1=CC=CC=C1O CDAWCLOXVUBKRW-UHFFFAOYSA-N 0.000 claims description 4
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 claims description 4
- 150000001408 amides Chemical class 0.000 claims description 4
- 239000003637 basic solution Substances 0.000 claims description 4
- 229910052794 bromium Inorganic materials 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 208000010877 cognitive disease Diseases 0.000 claims description 4
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 claims description 4
- YCOZIPAWZNQLMR-UHFFFAOYSA-N pentadecane Chemical compound CCCCCCCCCCCCCCC YCOZIPAWZNQLMR-UHFFFAOYSA-N 0.000 claims description 4
- JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 claims description 4
- RSJKGSCJYJTIGS-UHFFFAOYSA-N undecane Chemical compound CCCCCCCCCCC RSJKGSCJYJTIGS-UHFFFAOYSA-N 0.000 claims description 4
- 206010012289 Dementia Diseases 0.000 claims description 3
- 239000005697 Dodecan-1-ol Substances 0.000 claims description 3
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 3
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 claims description 3
- SNRUBQQJIBEYMU-UHFFFAOYSA-N dodecane Chemical compound CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 claims description 3
- 150000002576 ketones Chemical class 0.000 claims description 3
- 208000005264 motor neuron disease Diseases 0.000 claims description 3
- CVICEEPAFUYBJG-UHFFFAOYSA-N 5-chloro-2,2-difluoro-1,3-benzodioxole Chemical group C1=C(Cl)C=C2OC(F)(F)OC2=C1 CVICEEPAFUYBJG-UHFFFAOYSA-N 0.000 claims description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 2
- 208000028698 Cognitive impairment Diseases 0.000 claims description 2
- 208000026097 Factitious disease Diseases 0.000 claims description 2
- 208000026072 Motor neurone disease Diseases 0.000 claims description 2
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 2
- 208000024777 Prion disease Diseases 0.000 claims description 2
- 206010052276 Pseudodementia Diseases 0.000 claims description 2
- 208000017442 Retinal disease Diseases 0.000 claims description 2
- 206010038923 Retinopathy Diseases 0.000 claims description 2
- 206010039966 Senile dementia Diseases 0.000 claims description 2
- 206010008129 cerebral palsy Diseases 0.000 claims description 2
- 230000006735 deficit Effects 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 claims description 2
- 210000002816 gill Anatomy 0.000 claims description 2
- 208000002780 macular degeneration Diseases 0.000 claims description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 2
- 201000000980 schizophrenia Diseases 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- 230000001052 transient effect Effects 0.000 claims description 2
- FAQYAMRNWDIXMY-UHFFFAOYSA-N trichloroborane Chemical compound ClB(Cl)Cl FAQYAMRNWDIXMY-UHFFFAOYSA-N 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 21
- 229960000583 acetic acid Drugs 0.000 claims 4
- 125000004159 quinolin-2-yl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C([H])C(*)=NC2=C1[H] 0.000 claims 3
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- XFGANBYCJWQYBI-UHFFFAOYSA-N 11-bromoundecan-1-ol Chemical compound OCCCCCCCCCCCBr XFGANBYCJWQYBI-UHFFFAOYSA-N 0.000 claims 1
- NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 claims 1
- 206010002660 Anoxia Diseases 0.000 claims 1
- 241000976983 Anoxia Species 0.000 claims 1
- 208000016988 Hemorrhagic Stroke Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-Chlorosuccinimide Substances ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 150000001299 aldehydes Chemical class 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 230000007953 anoxia Effects 0.000 claims 1
- ASIDMJNTHJYVQJ-UHFFFAOYSA-N bromo-dodecanol Chemical compound OCCCCCCCCCCCCBr ASIDMJNTHJYVQJ-UHFFFAOYSA-N 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 claims 1
- 239000007789 gas Substances 0.000 claims 1
- 239000012362 glacial acetic acid Substances 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 201000010901 lateral sclerosis Diseases 0.000 claims 1
- 229940050176 methyl chloride Drugs 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 150000007660 quinolones Chemical class 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 238000005481 NMR spectroscopy Methods 0.000 description 119
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 43
- 125000003118 aryl group Chemical group 0.000 description 16
- 239000000543 intermediate Substances 0.000 description 15
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 125000000753 cycloalkyl group Chemical group 0.000 description 14
- 125000001072 heteroaryl group Chemical group 0.000 description 13
- 101000632319 Homo sapiens Septin-7 Proteins 0.000 description 12
- 102100027981 Septin-7 Human genes 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- 125000003545 alkoxy group Chemical group 0.000 description 11
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 11
- 125000005843 halogen group Chemical group 0.000 description 10
- 239000011541 reaction mixture Substances 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 125000004432 carbon atom Chemical group C* 0.000 description 9
- 238000003818 flash chromatography Methods 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 125000004442 acylamino group Chemical group 0.000 description 6
- 125000003342 alkenyl group Chemical group 0.000 description 6
- 125000004414 alkyl thio group Chemical group 0.000 description 6
- 125000004429 atom Chemical group 0.000 description 6
- 125000001188 haloalkyl group Chemical group 0.000 description 6
- 229910052740 iodine Inorganic materials 0.000 description 6
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- 125000006413 ring segment Chemical group 0.000 description 6
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 5
- 150000001298 alcohols Chemical class 0.000 description 5
- 125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 5
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 5
- 125000004181 carboxyalkyl group Chemical group 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 0 CCC1C(C[C@]2([C@@](C)**)N[C@@](C)C=CC2)=C1 Chemical compound CCC1C(C[C@]2([C@@](C)**)N[C@@](C)C=CC2)=C1 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 4
- 125000000304 alkynyl group Chemical group 0.000 description 4
- 125000001589 carboacyl group Chemical group 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 4
- 230000014511 neuron projection development Effects 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000001301 oxygen Chemical group 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 229910052717 sulfur Chemical group 0.000 description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- 101000979249 Homo sapiens Neuromodulin Proteins 0.000 description 3
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 3
- 102100023206 Neuromodulin Human genes 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 3
- 125000003282 alkyl amino group Chemical group 0.000 description 3
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000019439 ethyl acetate Nutrition 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 125000001841 imino group Chemical group [H]N=* 0.000 description 3
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 150000003248 quinolines Chemical class 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- JCRQQQUHRPKCRV-UHFFFAOYSA-N 1-bromo-2-methylidenecyclopropane Chemical compound BrC1CC1=C JCRQQQUHRPKCRV-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 238000012347 Morris Water Maze Methods 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 125000005741 alkyl alkenyl group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- FUSUHKVFWTUUBE-UHFFFAOYSA-N buten-2-one Chemical compound CC(=O)C=C FUSUHKVFWTUUBE-UHFFFAOYSA-N 0.000 description 2
- AYOCQODSVOEOHO-UHFFFAOYSA-N carbamoyl carbamate Chemical compound NC(=O)OC(N)=O AYOCQODSVOEOHO-UHFFFAOYSA-N 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 125000004043 oxo group Chemical group O=* 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- RDOWQLZANAYVLL-UHFFFAOYSA-N phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 2
- SMUQFGGVLNAIOZ-UHFFFAOYSA-N quinaldine Chemical compound C1=CC=CC2=NC(C)=CC=C21 SMUQFGGVLNAIOZ-UHFFFAOYSA-N 0.000 description 2
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 2
- 238000006798 ring closing metathesis reaction Methods 0.000 description 2
- 238000010825 rotarod performance test Methods 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 208000020431 spinal cord injury Diseases 0.000 description 2
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- CYNYIHKIEHGYOZ-UHFFFAOYSA-N 1-bromopropane Chemical compound CCCBr CYNYIHKIEHGYOZ-UHFFFAOYSA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
- SQUZDHVARUTGDI-UHFFFAOYSA-N 2-(10-hydroxydecyl)quinolin-8-ol Chemical class C1=CC=C(O)C2=NC(CCCCCCCCCCO)=CC=C21 SQUZDHVARUTGDI-UHFFFAOYSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- YNTJKQDWYXUTLZ-UHFFFAOYSA-N 2-(3-chlorophenoxy)propanoic acid Chemical compound OC(=O)C(C)OC1=CC=CC(Cl)=C1 YNTJKQDWYXUTLZ-UHFFFAOYSA-N 0.000 description 1
- UYHOZWLAIXWGJB-UHFFFAOYSA-N 2-(9-hydroxynonyl)quinolin-8-ol Chemical compound C1=CC=C(O)C2=NC(CCCCCCCCCO)=CC=C21 UYHOZWLAIXWGJB-UHFFFAOYSA-N 0.000 description 1
- XCIZVKSCLVSDHN-UHFFFAOYSA-N 2-ethylquinoline Chemical compound C1=CC=CC2=NC(CC)=CC=C21 XCIZVKSCLVSDHN-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 125000004398 2-methyl-2-butyl group Chemical group CC(C)(CC)* 0.000 description 1
- VLRSADZEDXVUPG-UHFFFAOYSA-N 2-naphthalen-1-ylpyridine Chemical compound N1=CC=CC=C1C1=CC=CC2=CC=CC=C12 VLRSADZEDXVUPG-UHFFFAOYSA-N 0.000 description 1
- MUVDRQRFWBJETA-UHFFFAOYSA-N 2-propan-2-yloxyquinoline Chemical compound C1=CC=CC2=NC(OC(C)C)=CC=C21 MUVDRQRFWBJETA-UHFFFAOYSA-N 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- JHUUPUMBZGWODW-UHFFFAOYSA-N 3,6-dihydro-1,2-dioxine Chemical compound C1OOCC=C1 JHUUPUMBZGWODW-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- SLBPIHCMXPQAIQ-UHFFFAOYSA-N 8-hydroxyquinoline-2-carbaldehyde Chemical compound C1=C(C=O)N=C2C(O)=CC=CC2=C1 SLBPIHCMXPQAIQ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 101000983970 Conus catus Alpha-conotoxin CIB Proteins 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical group O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 241000790917 Dioxys <bee> Species 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 101150110799 ETFA gene Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 244000131360 Morinda citrifolia Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 206010036312 Post-traumatic epilepsy Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 101150051783 SWT1 gene Proteins 0.000 description 1
- 229910018143 SeO3 Inorganic materials 0.000 description 1
- 206010041591 Spinal osteoarthritis Diseases 0.000 description 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 1
- 239000005702 Tetradecan-1-ol Substances 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 208000016620 Tourette disease Diseases 0.000 description 1
- 241000009298 Trigla lyra Species 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 125000005237 alkyleneamino group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 150000001555 benzenes Chemical class 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- QNBJYIDSJFPLHM-UHFFFAOYSA-N benzyl n-carbamothioylcarbamate Chemical compound NC(=S)NC(=O)OCC1=CC=CC=C1 QNBJYIDSJFPLHM-UHFFFAOYSA-N 0.000 description 1
- 238000005574 benzylation reaction Methods 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- ZZRMYOZQUCUWFT-UHFFFAOYSA-N but-3-yn-2-amine Chemical compound CC(N)C#C ZZRMYOZQUCUWFT-UHFFFAOYSA-N 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 125000002579 carboxylato group Chemical group [O-]C(*)=O 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 101150091051 cit-1 gene Proteins 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 1
- MLUCVPSAIODCQM-NSCUHMNNSA-N crotonaldehyde Chemical compound C\C=C\C=O MLUCVPSAIODCQM-NSCUHMNNSA-N 0.000 description 1
- MLUCVPSAIODCQM-UHFFFAOYSA-N crotonaldehyde Natural products CC=CC=O MLUCVPSAIODCQM-UHFFFAOYSA-N 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 108010011222 cyclo(Arg-Pro) Proteins 0.000 description 1
- UZVGSSNIUNSOFA-UHFFFAOYSA-N dibenzofuran-1-carboxylic acid Chemical compound O1C2=CC=CC=C2C2=C1C=CC=C2C(=O)O UZVGSSNIUNSOFA-UHFFFAOYSA-N 0.000 description 1
- WBKFWQBXFREOFH-UHFFFAOYSA-N dichloromethane;ethyl acetate Chemical compound ClCCl.CCOC(C)=O WBKFWQBXFREOFH-UHFFFAOYSA-N 0.000 description 1
- MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- FVIZARNDLVOMSU-UHFFFAOYSA-N ginsenoside K Natural products C1CC(C2(CCC3C(C)(C)C(O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O FVIZARNDLVOMSU-UHFFFAOYSA-N 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- 125000005549 heteroarylene group Chemical group 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
- 125000001261 isocyanato group Chemical group *N=C=O 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 125000001620 monocyclic carbocycle group Chemical group 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000006764 neuronal dysfunction Effects 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000017524 noni Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005327 perimidinyl group Chemical group N1C(=NC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- RRDMEJDVORGSHF-UHFFFAOYSA-N phenarsazinine Chemical compound C1=CC2=NC3=C(C=CC=C3)[As]=C2C=C1 RRDMEJDVORGSHF-UHFFFAOYSA-N 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- MWWATHDPGQKSAR-UHFFFAOYSA-N propyne Chemical compound CC#C MWWATHDPGQKSAR-UHFFFAOYSA-N 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- MHKFWKVLUPCEAH-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1.C1=CN=C2C(O)=CC=CC2=C1 MHKFWKVLUPCEAH-UHFFFAOYSA-N 0.000 description 1
- SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 208000001413 spine osteoarthritis Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 125000000213 sulfino group Chemical group [H]OS(*)=O 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000004627 thianthrenyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3SC12)* 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000000464 thioxo group Chemical group S=* 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 125000006168 tricyclic group Chemical group 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
- C07D215/28—Alcohols; Ethers thereof with halogen atoms or nitro radicals in positions 5, 6 or 7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- US Patent Nos. 7,439.243 and 7,452.888 describe a series of quinolme derivatives useful for the treatment of CNS disorders, including Alzheimer ' s disease.
- US Patent No. 7,009.053 describe a series of quinolme derivatives useful for treatment of Alzheimer's disease, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis, stroke, ischemia, traumatic brain injury, spinal cord inj ury or osteoarthritis,
- the invention relates to a compound of Formula (1.) or a pharmaceutically acceptable salt, a solvate or hydrate, a prodrug, or a metabolite thereof:
- R 2 is hydrogen or halogen
- .R:' is hydrogen, halogen, (CrCg kyl, or (CrCs)a1koxy;
- R 4 is hydrogen, halogen, (C(-Cs)alkyl. (C r € 3 ⁇ 4 )aikoxy, or (CrC cramp)haioalkyl;
- R 5 is hydrogen or (Cr €;3 ⁇ 4)alkanol
- R 6 is hydrogen
- R 7 is hydrogen, (Ci 1 ⁇ 2o)alkanol, (CrCs)alkylene iC 3 -Cs)heteroc d l(Cj ⁇ 2o) ⁇ anol, (C ' r Cs)alkylene (C3-Cs)heterocydyKCrC2(>)alkyl, ⁇ Ci !8)alk> : lene(CrC«)alkylan3 ⁇ 4no(Ci-C ⁇ >)a]kynyl, (C3 ⁇ 4- Cs)alkyleneamino(C j-C 3 ⁇ 4j)al kanol , or (C f - Cs)alky leneami no(C i-C a>)aikanol (C j -C «)alkylene
- the invention relates to a method for preparing the compound as aforementioned, the method comprising:
- R ⁇ R 4 , - . and R 6 are each independently hydrogen; or
- R 4 , R , and R (> are each independently hydrogen and R* is Cl or
- R '" , R ⁇ R “ ⁇ and R (> are each independeiitiv hydrogen and R 4 is CF , F ⁇ CI, or Br; or R 3 , R R 6 are each independently hydrogen, R ' ' is OCt . and R 4 is CI; or
- R “ , R 4 is CI and R " ⁇ R 5 , * are each independently hydrogen
- R 5 is CH 3 FbCH 3 . CH(CH 3 )2, or benzv l, and
- R 3 , R 4 , R 5 , and R f> are each independently hydrogen and R' is C f?; or
- R 2 , R ' R s , and R 6 are each independently hydrogen and R 4 is Cl , F ? CI, or Br; or
- R" are each independently hydrogen, R 3 is OCH ? . and R 4 is CI; or
- R z , R 4 is CI and R ' ⁇ R ⁇ R" are each independently hydrogen;
- ' is CH 3 , CH 2 CH 3t CH ⁇ CJ3 ⁇ 4)2, CH 2 CH ⁇ CH 3 )2, or benzyl;
- R 2 , R ' . R 4 , R' ; and R* are each independently hydrogen or
- R 2 , R* R' ⁇ and R b are each independently hydrogen and R;' is CH3 ⁇ 4; or
- R ⁇ . R ⁇ R ⁇ and R" are each independently hydrogen and R 4 is CH*, F, CL or Br; or
- R ' l R 5 , R" are each independently hydrogen, R* is OCI3 ⁇ 4, and R 4 is CI; or K" is CI, and R is oa-h or
- R 2 , R 4 is CI and R:', R' R 6 are each independenily hydrogen: and
- R 7 is (CH ⁇ OH, (CH ⁇ wOH, (CH 2 ) n OH ⁇ (CH 2 )i 2 OH, (CH 2 )uOH, iCH 2 ) ! 5 OH,
- R ⁇ and ° are each independently hydrogen; or
- R 2 , R 4 , R'êt and * are each independently hydrogen and R -> is CFI 3 ; or
- R J , ⁇ R ' R 5 , and R" are each independently hydrogen and R* is C3 ⁇ 4 F, CI, or Br; or R ⁇ , R ' R ⁇ R" are each independently hydrogen, R-" is OCH 3 ⁇ 4 and R is CI; or
- R ? R 4 is CI and R ! , K R ⁇ R 6 are each independently hydrogen;
- R 7 is (CH 2 3 ⁇ 4 J OH 5 (CH 2 ) Kl OH ; (CH 2 ) n OH, (CH 2 ) 12 OH. (CH 2 )ijOH, (CH 2 ), $ OH; or
- R Ul is methyl, ethyl, 2-propyl, methylenecyclopropyl, or benzyl
- R is hydrogen, methyl ethyl, 2-propyl or inethySenecyclopropyi.
- R 1 is hydrogen, methyl, ethy l, 2-propyl, or methylenecyclopropyl., with 2(piperazin-l-yl) ethanol to obtain a compound of Formula (1), wherein R 3 is hydrogen, CH h C3 ⁇ 4CH 3 , CHsCHgCti fe. Cl fcCHiClfek or CFi(CFi 3 )3 ⁇ 4 R 2 , R 3 , R R ⁇ and R 6 are each independently hydrogen: and R ' is CH 2 (N(CH 2 Ci-i 2 ) 2 )CH 2 CFi 2 0H; or
- the invention reiates to a composition comprising a therapeutically effective amount of the compound as aforementioned, or a pharmaceutically acceptable salt a solvate or hydrate, a prodrug, or a metabolite thereof, and a pharmaceutically acceptable diluent or carrier.
- the invention relates to a composition comprising a compound as aforementioned, or a pharmaceutically acceptable salt a solvate or hydrate, a prodrug, or a
- the invention relates to a use of a compound as aforementioned in the manufacture of a medicament for treating a neurodegenerative disease.
- the medicament is for treating Alzheimer's disease.
- FiGs. lA-B show morphological analysis of the effects of compound C I 2 on fAf3 ⁇ 4 formation and dissociation of fAfis in the presence or absence of zinc ions.
- FIG. 2 shows compound C12 inhibiting polymerization of ⁇ in the absence of zinc ions.
- FiGs. 3A-B show compound C 1 2 acting as a neuroprotective agent targeting f ⁇ .
- FIG. 4 shows qtii.noli.iie derivatives-induced neurite outgrowth.
- FIG. 5 shows quinolme derivatives increased expression of GAP43 (a marker for neurite outgrowth).
- FIG. 6 shows the results of rotarod test.
- FiGs. 7A-.D show the results of Morris water maze test.
- FIG. 8 shows an increase in GAP43 level and decrease in fAp level in memory-deficit fA
- a dash (“-") that is not between two letters or symbols is used to indicate a point of attachment for a moiety or substituent
- the moiety -CONH2 is attached through the carbon atom.
- amino refers to -NHj.
- the amino group can be optionally substituted as defined herein for the term “substituted.”
- ' alkyiamino refers to -M 2 , wherein at least one R is alky i arid the second is alkyl or hydrogen.
- ac i amino refers to N(R)C ⁇ ::: 0)R, wherein each R is independently hydrogen, alky I . or aryl.
- alky refers to Cj-Ci3 ⁇ 4 hydrocarbon containing normal, secondary, tertiary or cyclic carbon atoms. Examples are methyl, ethyl, 1 -propyl, 2-propyi, J -butyl, 2-methyl-l -propyl (iso- butyl -CH 2 CH(CH 3 )2), 2 ⁇ butyl (sec-butyl.
- the a!kyi can be a monovalent hydrocarbon radical, as described arid exemplified above, or it can be a divalent hydrocarbon radical (i.e., alkylene).
- the alky can optionally be substituted with one or more alkoxy, halo, haloalkyl, hydroxy, h droxy alkyl, ar iJieteroaryl heterocycle, cycloalkyl, alkanoyl, alkoxycarbonyl, amino, imino, alkylammo, acylamino, nitro, tri.fluoromethy.1,
- alky lene 5" refers to a saturated, branched or straight chain or cyclic hydrocarbon radical of 1-18 cai'bon atoms, and having two monovalent radical centers deri ved by the removal of two hydrogen atoms from the same or different carbon atoms of a parent alkane.
- Typicai alk lene radicals include, but are not limited to: methylene ( ⁇ CHr-) -ethyiene (-CH 2 CH2-), U-propylene ( ⁇ CH 2 CH 2 CHr-X 1 ,4- butylene and the like.
- the alkylene can optionally be substituted with one or more alkoxy, halo, haloalkyl, hydroxy, hydroxy alkyl, aryl, heteroaryl, heterocycle, cycloalkyl, alkanoyl, alkoxy carbon l, amino, imino, alkylamino, acylamino, nitro, trilluoromethyi,
- each R x and R y are independently H, alkyl, alkenyl, aryl heteroar k heterocycle. cyc!oalkyl or hydroxy.
- the aikykne can optionally be at least partially unsaturated, ⁇ hereby providing an alkenyierie.
- alkynyl refers to a morsoradical branched or unbranched hydrocarbon chain, having a. point of complete unsaturauon (i.e., a carbon-carbon, sp triple bond), in one embodiment, the alkynyl group can have from 2 to 1 carbon atoms, or 2 to 6 carbon atoms. In another embodiment the alkynyl group can have from 2 to 4 carbon atoms. This term is exemplified by groups such as ethynyl, l-propynyl.
- alkynyl can be unsubstituted or substituted.
- alkoxy refers to the group alky 1-0-, where alky ) , is defined herein.
- Preferred alkoxy groups include, e.g., methoxy, ethoxy, »-propoxy. .i'o-propoxy, ?i-buioxy, tert-bvtoxy, .ve -butoxy, n-penioxy, »-hexoxy, l ,2---dimethylbutoxy s and the like.
- the alkoxy can optionally be substituted with one or more halo, haloalkyl, hydroxy, hydroxyalkyl. aryl, heteroaryl, heterocycle, cycloalkyL aikanoyl, alkoxycarbonyl, amino, imino, alkylamirto, acylamino, nitro, triffuoromethyJ,
- benzenesidfonyianii.no benzoyl, benzo l amino, benzovioxv, benzyl, benzyloxy, benzyloxycarbonyl, benz lthio, carbamoyl, carbamate, isocyannato, sulfamoyl, sulfinamoyl, sulfino, sulfa sulfoamino, thiosulfo, NR R y and'or COQR*, wherein each R* and R are independently H, alkyl, aikenyl, aryl, heteroaryl. heterocycle. cyc!oalkyl, or hydroxy .
- alkanot refers to a compound of a general formula ROR where R is alkyl, as defined herein.
- ary P refers to an unsaturated aromatic earbocycSic group of from 6 to 20 carbon atoms having a single ring (e.g. , phen l) or multiple condensed (fused) rings, wherein at least one ring is aromatic (e.g., naphthyl, dihydrophenanthrenyl, fiuorenyi, or anthryl ⁇ .
- Preferred aryls include phenyl, naphihyi and the like.
- the aryl can optionally be a divalent radical, thereby providing an arylene.
- Tire ar l can optionally be substituted with one or more alkyl, aikenyl, alkoxy, halo, haloalkyl, hydroxy, hydroxyalkyl, aryl, heteroaryl, heterocycle, cycloalkyl aikanoyl,
- R x and W are independently H, alkyl alkenyl aryl, heteroaryf heterocycle, cycloalkyl or hydroxy.
- aryloxy and ''arylalkoxy refer to, respectively, an aryl group bonded to an oxygen atom and an aralkyl group bonded to the oxygen atom at the alky! mostl . Examples include but are not limited to phenoxy, naphthyloxy, and benzyioxy.
- Carbocyele refers to a saturated, unsaturated or aromatic ring having 3 to 8 carbon atoms as a raonocycle, 7 to 12 carbon atoms as a bicycle, and up to about 30 carbon atoms as a pot cycle.
- Monocyclic carbocycles typically have 3 to 6 ring atoms, still more typically 5 or 6 ring atoms.
- Bieyclic carbocycles have 7 to 12 ring atoms, e.g., arranged as a icyclo [4,5], (5,5 ⁇ , ⁇ 5,6 ⁇ or [6,6] system, or 9 or 10 ring atoms arranged as a bicycio ⁇ 5.6 ⁇ or [6.6 ⁇ system.
- carbocycles include eyclopropyl. cyclobutyl, cyclopenlyl, l-cyclopent-l-eoyk l - ydopent-2-enyl, 1- eyelopeni-3-enyl, eyctohexyl l-cyclohex-l-enyi, l-cye!ohex-2-enyi, 1 -cyclohex-3-enyl, phenyl, spiryi and naphthyi.
- the carbocycle can be optionally substituted as described above for aikyl groups.
- cycloalkyl refers to cyclic alkyl groups of from 3 to 20 carbon atoms having a single cyclic ring or multiple condensed rings.
- Such cycloalkyl groups include, by way of example, single ring structures such as eyclopropyl, cyclobutyl, cyclopenlyl. cyclooetyi. and the like, or multiple ring structures such as adamantanyl, and the like.
- the cycloalkyl can optionally be substituted with one or more alkyl alkenyl, aJkoxy, halo, haloalkyl, hydroxy, hydroxy alkyl aryl, heteroary 1, heterocycle, cycloalkyl, alkanovl, aikoxycaxbony), amino, imino, alkylaroino, acyiarairio, riitro, triOuorometh l. trill norometho y, carboxy, earboxyalkyl, keto, ihioxo, alkylthio, a!k lsuifinyl, alkylsulfonyl, cyano.
- cycloalkyl of hydroxy can optionally be at least partially unsaturated, thereby providing a cycioalkenyl. Additionally, the cycloalkyl can optionally be a divalent radical, thereb providing a cycloalky!ene.
- an effective amount refers to an amount sufficient to effect beneficial or desired results. Determination of an effective amount for a given administration is well within the ordinary skill in the pharmaceutical arts.
- halo refers to fiuoro, chSoro, bromo, and iodo.
- ''halogen refers to fluorine, chlorine, bromine, and iodine.
- haioalky refers to alky! substituted by 1-4 halo groups, which may be the same or different.
- Representative haloa!kyl groups include trill uoromethyl, 3-fluorododecyL 12,12,12- trifiuorododecyl, 2-brornooctyI, 3 --bromo---6--chioiOheptyl. and the like.
- heteroaryP is a monocyclic, bicyclie, or tricyclic ring system containing one, two, or three aromatic rings aid containing at least one nitrogen, oxygen, or sulfur atom i an aromatic ring, and which can be unsubstituted or substituted.
- the heteroaryl can optionally be a divalent radical, thereby providing heteroarylene.
- heteroar l groups include, but are not limited to, 2H-pyrroiyl, 3H-indo ' lyI, 4H ⁇ qumoIizinyk 4nH---carbazolyl, acridinyl, benzo[d
- benzothiazoS i ⁇ - arboiinyl, carbazoi l, chromen l, cinnaoiinyl, dibenzo ⁇ b,d)furanyl, furazanyl, fury I, imidazoiyl, imidizoi l, indazolyl, indoiisin l, indoiyl, isobenzofuranyl, isoindoiyl, isoquinolyl, isotliiazoly!, isoxazolyS, naphrayridinyl, napthoj 2,3-6], oxazolyl, perimidinyl, phenanthridinyl, phenanthrolrayl, phenarsazin l, phenazinyl, phenothiazinyS, phenoxaihiim , phenoxa inyi,
- phthalazinyl, pteridin l. purin l, pyranyl, pyrazinvL pyrazolyl, pyridazinyl, pyridyi. pyrimidinyl, pyrimddinyl, pyrroiyL qumazolmyl, quino!yl. quinoxaUnyl, thiadiazolyl, thianthrenyl, thiazolyl, thienyl, triazoly ' l. and xaothenyl.
- die terra "heteroary denotes a monocyclic aromatic ring containing fi e or six ring atoms containing carbon and 1 , 2, 3, or 4 heteroatoms independently selected from the group non-peroxide oxygen, sulfur, and ( ) wherein is absent or is H, O, alky I. phenyl, or benzyl
- heteroaryl denotes an ortho-fused bicyclie heterocycle of about eight to ten ring atoms derived therefrom, particularly a benz -derivative or one derived by fusing a propylene, or tefiramethylene diradieal thereto.
- the heteroaryl can optionally be substituted with one or more alkyl, a!ken l, alkoxy, halo, haloalkyi, hydroxy, hydroxy alkyl, aryl heteroaryl, heterocycle, cycioalkyl, alkanoyi,
- alkox earhonyl amino- iniino, alkylamino.
- acyl amino, nitro, trifluoromethyl, trifluoromethoxy, carboxy, carboxya!kyl, keto, thioxo, alkylmio, alkylsulfinyl, alkylsulfonyl. cyano. acetamido.
- benzenesulfoiiySaniino benzoyl, benzoyl amino, ben/.oyloxy, benzyl, benzyloxv. benzyloxy carbonyi, benzylthio, carbamoyl, carbamate, isoeyann&to. sulfamoyl, sulfinamoyl, suiiwo. sulfo, sulfoamino, thiosulfo, NR*R y and/or COOR ; , wherein each R s and R are independently H, alkyl, a!kenyl, and, heteroaryl heterocycle, cycioalkyl, or hydroxy.
- heterocycle or '"heterocyclv * refers to a saturated or partially unsaturated ring system, containing at least one heteroatom selected from ihe group oxygen, nitrogen, and sulfur, and optionally substituted with alky I, or ⁇ , wherein R h is hydrogen or alfcyl.
- heterocycle is a monocyclic, bicyclk, or tricyclic group containing one or more heteroatoms selected from the group oxygen, nitrogen, a d sulfur,
- heterocycle groups include 1,3- dilrydrobenzofuran, 1,3-dioxolane, 1,4-dioxane, l ,4-- 3ithiane, 2H--pyran, 2-py-raxoline, 4 /-p ran, chromanyl, imidazolidmyl, imidazolinyi, indolinyl, isochromanyl, isoindolinyl, morpholine, piperazinyi, piperidine, piperidyl, pyrazolidine, pyrazoiidinyi, pyrazoUnyl, pyrrolidine, pyrroiine, quinuclidine, and tliiomorpholine.
- the heterocycle can optionally be a div alent radical, thereby providing a heterocyciene.
- the heterocycle can optionally be substituted with one or more aJkyl, alkenyl, alkoxy, halo, haloalkyi, hydroxy, hydroxy alky I, ar l, heteroar l, heterocycle, cyeloalkyi, alkanoyl, a!koxycarbonyl, amino, imino. alkylamino, aeylaniino, nitro, triiluoromethyl,
- benzenesulfonyiamino benzoyl, benzoyl amino, benzoyloxy, benzyl, benz loxy, teroyloxycarbonyl, benzy!thio, carbamoyl carbamate, isocyannato, sulfamoyl, sulfinamoyl, sulfmo, sulfo, snlfoammo, thiosu!fo, NR*R- V and/or COOR*, wherein each R and R 5 are independently !L alkyl, alkenyl, aryl, heteroaryl, heterocycle, cycloalkyl, or hydroxy.
- nitrogen heteroeycles and heteroaryls include, but are not limited to, pyrrole, imidazole, pyrazole. pyridine, pyra ine, pyrimidme, pyridazine, indoiizine, isoindole, indole, indazoie, purine, quino!izioe, isoquinoline, quinoiine, phthalaane, naphthylpyridine. quinoxaline, quinazoline, cinnoiine, pteridine, carbazole. carboline, phenanthridine, acridine.
- phenanthroline isothiazoie, phenazine, isoxazole, phenoxazme, phenothiazine, rmidazolidine, imidazoline, piperidine, piperazine, indoline, morpholino, piperidinyL teirahydrofuranyl, and roe like as well as N-aikox -nitrogen containing heterocy cl es.
- hydrate refers to the complex where the solvent molecule is water.
- '"metabolite ' ' refers to any compound of the Formula.0) produced in vivo or in ' vitro from the parent drug, or its prodrugs.
- the pharmaceutically acceptable salts of the compounds described herein can be synthesized from the parent compound, which contains a. basic or acidic moiety, by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid m water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of many suitable salts are found in Remington: The Science and Practice of Pharmacy. 21 st edition, Lippincott Williams & Wilkins, (2005).
- prodrugs refer to a compound that is metabolized, for example hydroi zed or oxidized, in the host to form a compound of the Formula (I).
- Typical examples of prodrugs include compounds that have biologically labile protecting groups on a functional moiety of the active compound.
- Prodrugs include compounds thai can be oxidized, reduced, animated, deaminated, hydroxylated, dehydroxylaied. hydrolyzed, dehydrolyzed, alkylated, dealkylated, acylated, deacylated, phosphorylated. dephosphorylated to produce the active compound.
- the prodrug can be readily prepared from the compounds of Formula (I) using methods known in the art. See, e.g. See Notari, R E., "Theory and Practice of Prodrug Kinetics," Methods in E ymo gy, 1 12:309 323 (1985); Bodor, N., “Novel Approaches in Prodrug Design/ * Drugs of (he Future, 6(3): 165 182 (1981 ); and Bundgaard, H., ' " Design of Prodrugs: Bioreversible-Derivatives for Various Functional Groups and Chemical Entities. '' in Design of Prodrugs (H. Bundgaard, ed. ),
- solute refers to a complex of variable stoichiometry formed by a solut (in this invention, a compound of Formula I, or a salt or physiologically functional derivative thereof) and a solvent.
- solvents for the purpose of the invention, should not interfere with the biological acti vity of the solute.
- suitable solvents include, but are not limited to water, methanol, ethanol and acetic acid.
- the solvent used is a pharmaceutically acceptable solvent.
- suitable pharmaceutically acceptable solvents include water, ethanol, and acetic acid.
- room temperature refers to a temperature in the range of about 20° C to about 30T.
- substituted is intended to indicate thai one or more hydrogens on the atom indicated is replaced with a selection from the indicated group(s), provided that the indicated atom's normal valency is not exceeded, and that the substitution results in a stable compound.
- Suitable indicated groups include, e.g., alky I, alkenyl, alkyiidenyi, alkenyiidenyl, aikoxy, halo, haloalkyl, hydroxy, hydroxy alky .1, arvl, heteroaryl, heterocycJe, cycloalkyl, alkanoyl, acyloxy, aikox carbonyl, amino, imino, alkylarnino, acyl amino, nitro, trifluoromethyl, trifluoromethoxy, carboxy, carboxyalkyl, keto, thioxo.
- treating or “treat” or “treatment” refer to obtaining a desired pharmacologic and or physiologic effect.
- the effect may be prophylactic in terms of completely or partially preventing a disease or symptom thereof and/or may be therapeutic in terms of a partial or complete cure for a disease and/or adverse affect attributable to the disease.
- the invention relates to multifunctional quinoline derivatives having following properties: metal chelation, clearance of reactive oxygen species, anti-aggregation, neurite outgrowth and neuron proliferation. They are useful for treating neurondegeneratrve disease involving neuronal toxicity or dysfunction induced by oxidative stress and other disorders associated with misfokling protein aggregation, in animal model, quinoline derivatives (B3 or C I 2) at 1 to 100 mg/kg, preferable 1 to 10 mg/kg, i.p. daily) were found to improve memory of micewithout causing significant toxicit .
- the invention relates to a compound of Formula (i) or a. pharmaceutically acceptable salt, a solvate or hydrate, a prodrug, or a metabolite thereof:
- R 5 is hydrogen, (Ci-C 8 )alkyl_ (CrC s )ajkylene(C 3 'Cs)wcloalkyi, iC C s )teloalkyl, or (C Cs)alkylene(C6-C3 ⁇ 4))aiyi;
- R' is hydrogen or halogen
- R "! is hydrogen, halogen, (CVCs)aikyL or (Ci-Cs)alkoxy;
- R 4 is hydrogen, halogen, (Cj-Cs)aikyL (Ci-Cs)alkoxy, or (CrCyjhaloalkyl;
- R 5 is hydrogen or (C.t-C.3 ⁇ 4))aJkanol
- R ft is hydrogen; and R 7 is hydrogen, ( Qjo)aikarioS, fC i-Cs ⁇ aikylerie (C ⁇ -C ⁇ etero ⁇ dyliCj-CaoJaikiaiol, (Cj- Cg)a!kylene (C j-Cs)heterocyc1 yi (C rCa aik l t (Cr g)alkyl ie(Ci- Cclalky iaminoCC 3 -C3 ⁇ 4)al kynyi, (C j - C1 ⁇ 2)a!kyleneamino(CrC2o ⁇ alkancsl 5 or (Cr 1 ⁇ 4)a!kyleneamsno ⁇ Ci-C2o)aIkaooI(CrCs)alk ⁇ 1eite Rintituted(C C 2 o)heteroaryi.
- R' is hydrogen, €H 3 , CH-2CH3, CH(CH ⁇ , ClfeCitfCHsfe, CF 3 , or benzyl;
- R 2 is hydrogen, F, or CI
- R 3 is hydrogen, F. CI, CH 3f or OCH ;
- R 4 is hydrogen. F, CI, Br, C3 ⁇ 4, OC3 ⁇ 4. or CF 3 ;
- R 5 is hydrogen. (CH 2 ) repeatGH, or (CH 2 ) l2 0H;
- R ft is hydrogen
- R 7 is hydrogen, (CH 2 )90H ? (CH 2 )u>OH 5 ((3 ⁇ 4) ⁇ ⁇ , ⁇ C3 ⁇ 4)» 2 OH, (CH 2 ) 13 OH, (CH ⁇ OH,
- R ! is hydrogen, CH S , CH 2 CH 3 , C.H(C3 ⁇ 4> 2 , CB 2 CH(CH,) 2 , C3 ⁇ 4CH(CH 2 ) 3 ⁇ 4 C 3 ⁇ 4 or benzyl;
- R “ , R 4 , R ⁇ and R" are each independently hydrogen;
- R 7 is (OfefeOH, (CH 2 ) u >OH, (CH 2 ) n OH 5 (CH 2 )i 2 OH, ⁇ CH 2 )iiOH, (CH 2 ) l4 0H,
- R' is hydrogen, O F, CH 2 CHs, CrfjCf!fCHsk C%CBiCB 2 ) 3 ⁇ 4 or CH(CH 3 >2;
- R "? , R 3 , R', and R e are each independently hydrogen
- R* is CHj, F. CI, Br, Cf 3 , or OCH 3 ;
- R 7 is (CH 2 )i>OH, (CB 2 )K' ( OH, (CH ⁇ nOH, (CH 2 ⁇ J2 OB, (C ⁇ DOH. (CH 2 ) ls OH ⁇
- R* is hydrogen, CB 3 , CH 2 C3 ⁇ 4, CH(CH 2 > 2 , or C3 ⁇ 4CH(CH2) 2 ;
- R , R 4 are each independently CI
- R.”', R' and R" are each independently hydrogen;
- R 7 is (CH 2 )uOH, CH 2 NH(CH 2 )sOH. or C3 ⁇ 4N(C3 ⁇ 4)CH 2 C-CH.
- R J is hydrogen, ⁇ 3 ⁇ 4, CH 2 CH. CHsCHiCH a, CB 2 CH(CH 2 ) 2 , CH(CH 3 ⁇ 2 , or benzyl;
- R' " , R ⁇ R 4 , R (> . and R' are each independently hydrogen; and ' is «3 ⁇ 4)uGH or (CH 2 ⁇ I2 OH.
- R* is C3 ⁇ 4
- R ⁇ R 5 , and R 6 are each independently hydrogen
- R "1 and R4 are each independently OCH3 or CI;
- the compound is selected from the group consisting of 9-( 8-(benzy I oxy )q uinolin-2-yj)n onan- 1 -oL 10-(8-(benzy loxy)q uinol in-2-y !decatv 1 -ol, 1 1 -(8 - (benzy!oxy)qninolin-2-y!ur)decan-t -ol.
- the invention relates to a composition
- a composition comprising a compound as
- the neurodegenerative disease is selected from the group consisting of Alzheimer's disease, amyotrophic lateral scierosis (ALS), cataract cognitive disorder, cerebral ischaemia stroke, cerebral palsy; stroke, haemorrhagie stroke, Creotzfeldt-Jacob disease, spongiform encephalopathy, Mad Cow disease, dementia, depression. Down's syndrome, epilepsy, post- traumatic epilepsy, frontolemporal dementia.. Gilles de ia Tourette's syndrome, Haiierhoden- Spaiz disease, Huntington's disease, Levvy body disease, Parkinson ' s disease, cognitive impairment, learning deficit, macular degeneration, memory deficit, multiple sclerosis, multiple system atrophy, motor neuron disease. Pick's disease, progressive supranuclear palsy, pseudo dementia, retinopathy, senile dementia, schizophrenia transient anoxial induced neurodegeneration, pain, brain traumatic- injury, and spinal cord injury.
- ALS amyotrophic lateral scierosis
- Reagents and conditions (a) Mel, K 2 CO acetone, r.t 10 h.; (b) 1 ) LHMDS, THF, 0 D C, 1 h.;
- Reagents and conditions (a) Ethyl iodide or 2-bronropropan.e, 3 ⁇ 4Ci3 ⁇ 4, DMF, 60 '" 'C. 14 h. (b) 1) LHMDS, THE 0 1 h.; 2) RT, 12 - 30 h.
- N-chlorosuccini raids (0.3 g, 2.25 mmoi) was added to a stirred solution of compounds B in CHCI 3 (20 ml) for 48 h.
- the reaction mixture was poured into crushed ice and extracted with CH 2 CI 2 (20ml X 2).
- the extract was purified by column, chromatography with Hex/EA (3: 1) and recrystai Sized to gi ve compound (0.1 g, 49%).
- Reagents and conditions (a) HQ. iCI. ? , glacial HOAe, 1 i; ; 0. 6 h, rt.
- Reagents and conditions (a) methyl vinyl ketone, HCL reflux, (b) Mel. sCCh, acetone, rt 8h; Elf or 2 ⁇ bromopropane or methylenecyclopropyl bromide, K2CO3, DMF, 60 6 C, (c) I) LH.MDS, THF, 0 °C, 1 h.: 2) Br(CH 2 )»..i H, rt. (d) BnBr. KOM, EtOH, reflux, (e) H 3 ⁇ 4 Pd/C, MeOH, rt 24 h.
- T3 ⁇ 4e intermediate INT was synthesized through ring closure from 2-arninophenol reacted with methyl vin l ketone.
- INT I was reacled with various aJkyl halides to afford 8-alkoxy- 4methylquino.)me derivatives as intermediates.
- Corresponding Brt ' CHs iOH was reacted with intermediates to synthesize series of compounds 3 and I.
- the protective group J was removed by hydrogenaiiori (method iliustraied in example I) to obtain compound K.
- TSie intermediate was synthesized through ring closure from 2 rifluoromethoxy aniline reacied with crotoiialdehyde. Intermediate was reacted with corresponding Br(Ci3 ⁇ 4) tl .,iOH (as illustrated above) to synthesize series compounds L.
- Reagents and conditions (a) SeO3 ⁇ 4 dioxane, 50 to 80 °C; (b) N-methy!propagylaraine or 2- (pipera .in-1 -yl) ethano! or NHaiCHa )n-i OH, NaBH(OAc);;, l,2 ⁇ dkhloroeihane, rt.
- FIG. lA shows C12 inhibited ⁇ aggregation in the presence or absence of zinc ions using a microscopy analysis after Congo red staining.
- FIG. IB and F1G.2 show that C1.2 dissolved preformed ⁇ aggregates.
- HQs. 3A-B show that compounds C I 2, CQ and €12 intermediate protected neuron cells from zinc-induced ⁇ ' ⁇ . Only compound C 12 was effective toward zinc-tree aggregates (FIG, 3B).
- FIG. 4 shows induction of neurite outgrowth triggered by compound C 12 on undifferentiated PCI 2 cells.
- FIG, 5 shows quinoline derivatives increased expression of GAF43.
- FIG, 6 shows compound C 12 and B3 improved performance of learning in ⁇ -induced memor -deficit mice.
- FIG. 8 shows an increase in GAP43 level and decrease in fAp level in memory-deficit fAp-lesioned mice by compound CI 2.
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2013385618A AU2013385618B2 (en) | 2013-04-02 | 2013-04-02 | Multifunctional quinoline derivatives as anti-neurodegenerative agents |
CN201380075030.2A CN105452224B (en) | 2013-04-02 | 2013-04-02 | Multi-functional quinoline as anti-nerve degeneration agent |
RU2015137621A RU2642466C2 (en) | 2013-04-02 | 2013-04-02 | Multifunctional quinoline derivatives as antineurodegenerative agents |
JP2016506301A JP6153179B2 (en) | 2013-04-02 | 2013-04-02 | Multifunctional quinoline derivatives as anti-neurodegenerative agents |
PCT/US2013/034960 WO2014163622A1 (en) | 2013-04-02 | 2013-04-02 | Multifunctional quinoline derivatives as anti-neurodegenerative agents |
BR112015024472A BR112015024472A2 (en) | 2013-04-02 | 2013-04-02 | multifunctional quinoline derivatives as anti-neurodegenerative agents |
KR1020157026392A KR101802048B1 (en) | 2013-04-02 | 2013-04-02 | Multifunctional quinoline derivatives as anti-neurodegenerative agents |
EP13881032.0A EP2981525A4 (en) | 2013-04-02 | 2013-04-02 | Multifunctional quinoline derivatives as anti-neurodegenerative agents |
IL241295A IL241295A0 (en) | 2013-04-02 | 2015-09-08 | Multifunctional quinoline derivatives as anti-neurodegenerative agents |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2013/034960 WO2014163622A1 (en) | 2013-04-02 | 2013-04-02 | Multifunctional quinoline derivatives as anti-neurodegenerative agents |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2014163622A1 true WO2014163622A1 (en) | 2014-10-09 |
WO2014163622A8 WO2014163622A8 (en) | 2014-11-13 |
Family
ID=51658752
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2013/034960 WO2014163622A1 (en) | 2013-04-02 | 2013-04-02 | Multifunctional quinoline derivatives as anti-neurodegenerative agents |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP2981525A4 (en) |
JP (1) | JP6153179B2 (en) |
KR (1) | KR101802048B1 (en) |
CN (1) | CN105452224B (en) |
AU (1) | AU2013385618B2 (en) |
BR (1) | BR112015024472A2 (en) |
IL (1) | IL241295A0 (en) |
RU (1) | RU2642466C2 (en) |
WO (1) | WO2014163622A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016171533A1 (en) * | 2015-04-23 | 2016-10-27 | 대한민국(관리부서:국립수산과학원) | Novel microorganism having antibacterial activity and method for producing pseudane using same |
EP3466931A4 (en) * | 2016-05-27 | 2019-11-27 | Guangdong University Of Technology | Tetradentate chelating monoquinoline derivative, manufacturing method thereof, and application of same as metal ion regulator for neurodegenerative disease |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102281647B1 (en) * | 2020-12-09 | 2021-07-30 | 메디케어제약 주식회사 | Method of producing a derivative-piperazine |
CN113527200B (en) * | 2021-05-27 | 2022-12-02 | 北京斯利安药业有限公司 | Preparation method of cloquinadol |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7009053B2 (en) | 2002-04-30 | 2006-03-07 | Yungjin Pharmaceuticals Co., Ltd. | Quinoline derivatives as caspase-3 inhibitor, preparation for producing the same and pharmaceutical composition comprising the same |
US20060089380A1 (en) * | 2002-07-16 | 2006-04-27 | Prana Biotechnology Ltd. | 8-Hydroxy quinoline derivatives |
WO2008014602A1 (en) * | 2006-07-25 | 2008-02-07 | Envivo Pharmaceuticals, Inc. | Quinoline derivatives |
US7439243B2 (en) | 2003-09-25 | 2008-10-21 | Glaxo Group Limited | Piperazinyl-quinoline derivatives useful for the treatment of CNS disorders |
US7452888B2 (en) | 2002-03-27 | 2008-11-18 | Glaxo Group Limited | Quinoline derivatives and their use as 5-ht6 ligands |
US20090227626A1 (en) * | 2005-08-04 | 2009-09-10 | Palumed S.A. | Novel polyquinoline derivatives and therapeutic use thereof |
US20110301163A1 (en) * | 2008-10-06 | 2011-12-08 | The Johns Hopkins University | Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and sirt1, and methods of treating disorders |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3682927A (en) * | 1968-06-15 | 1972-08-08 | Massimo Carissimi | 5,7-bichloro-8-hydroxy-2-acetylamino quinoline |
GB9127306D0 (en) * | 1991-12-23 | 1992-02-19 | Boots Co Plc | Therapeutic agents |
US5589484A (en) * | 1992-10-27 | 1996-12-31 | Janssen Pharmaceutica N.V. | 4-quinolinyl derivatives |
ES2162319T3 (en) * | 1996-08-13 | 2001-12-16 | Gerolymatos P N Sa | USE OF THE CLIOQUINOL CHELATING AGENT FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE. |
WO1999002520A1 (en) * | 1997-07-07 | 1999-01-21 | Kowa Co., Ltd. | Diamine derivatives and pharmaceutical containing the same |
FR2819507B1 (en) * | 2001-01-17 | 2007-09-28 | Inst Rech Developpement Ird | SUBSTITUTED QUINOLINES FOR THE TREATMENT OF PROTOZOAN AND RETROVIRUS CO-INFECTIONS |
WO2004076386A2 (en) * | 2003-02-25 | 2004-09-10 | Topotarget Uk Limited | Carbamic acid compounds comprising a bicyclic heteroaryl group as hdac inhibitors |
WO2005035534A1 (en) * | 2003-10-08 | 2005-04-21 | Ono Pharmaceutical Co., Ltd. | Heterocyclic bicyclo ring and heterocyclic tricyclo ring compounds and drugs comprising the same |
US20050131042A1 (en) * | 2003-12-11 | 2005-06-16 | Flentge Charles A. | HIV protease inhibiting compounds |
AU2011258217B2 (en) * | 2010-05-26 | 2016-12-15 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
CN102526052B (en) * | 2012-01-19 | 2013-10-09 | 华南师范大学 | Application of 2-gylcosyl chinoline compound in preparing acetylcholine esterase resisting medicines |
-
2013
- 2013-04-02 CN CN201380075030.2A patent/CN105452224B/en not_active Expired - Fee Related
- 2013-04-02 JP JP2016506301A patent/JP6153179B2/en not_active Expired - Fee Related
- 2013-04-02 BR BR112015024472A patent/BR112015024472A2/en not_active IP Right Cessation
- 2013-04-02 EP EP13881032.0A patent/EP2981525A4/en not_active Withdrawn
- 2013-04-02 AU AU2013385618A patent/AU2013385618B2/en not_active Ceased
- 2013-04-02 WO PCT/US2013/034960 patent/WO2014163622A1/en active Application Filing
- 2013-04-02 RU RU2015137621A patent/RU2642466C2/en not_active IP Right Cessation
- 2013-04-02 KR KR1020157026392A patent/KR101802048B1/en active IP Right Grant
-
2015
- 2015-09-08 IL IL241295A patent/IL241295A0/en unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7452888B2 (en) | 2002-03-27 | 2008-11-18 | Glaxo Group Limited | Quinoline derivatives and their use as 5-ht6 ligands |
US7009053B2 (en) | 2002-04-30 | 2006-03-07 | Yungjin Pharmaceuticals Co., Ltd. | Quinoline derivatives as caspase-3 inhibitor, preparation for producing the same and pharmaceutical composition comprising the same |
US20060089380A1 (en) * | 2002-07-16 | 2006-04-27 | Prana Biotechnology Ltd. | 8-Hydroxy quinoline derivatives |
US7439243B2 (en) | 2003-09-25 | 2008-10-21 | Glaxo Group Limited | Piperazinyl-quinoline derivatives useful for the treatment of CNS disorders |
US20090227626A1 (en) * | 2005-08-04 | 2009-09-10 | Palumed S.A. | Novel polyquinoline derivatives and therapeutic use thereof |
WO2008014602A1 (en) * | 2006-07-25 | 2008-02-07 | Envivo Pharmaceuticals, Inc. | Quinoline derivatives |
US20110301163A1 (en) * | 2008-10-06 | 2011-12-08 | The Johns Hopkins University | Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and sirt1, and methods of treating disorders |
Non-Patent Citations (2)
Title |
---|
"Remington: The Science and Practice of Pharmacy", 2005, LIPPINCOTT, WILLIAMS & WILKINS |
See also references of EP2981525A4 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016171533A1 (en) * | 2015-04-23 | 2016-10-27 | 대한민국(관리부서:국립수산과학원) | Novel microorganism having antibacterial activity and method for producing pseudane using same |
EP3466931A4 (en) * | 2016-05-27 | 2019-11-27 | Guangdong University Of Technology | Tetradentate chelating monoquinoline derivative, manufacturing method thereof, and application of same as metal ion regulator for neurodegenerative disease |
Also Published As
Publication number | Publication date |
---|---|
AU2013385618A1 (en) | 2015-09-24 |
KR20150136070A (en) | 2015-12-04 |
JP2016515617A (en) | 2016-05-30 |
KR101802048B1 (en) | 2017-12-28 |
WO2014163622A8 (en) | 2014-11-13 |
JP6153179B2 (en) | 2017-06-28 |
RU2642466C2 (en) | 2018-01-25 |
EP2981525A4 (en) | 2016-12-21 |
AU2013385618B2 (en) | 2017-01-05 |
BR112015024472A2 (en) | 2017-07-18 |
CN105452224B (en) | 2017-12-26 |
RU2015137621A (en) | 2017-05-11 |
CN105452224A (en) | 2016-03-30 |
IL241295A0 (en) | 2015-11-30 |
EP2981525A1 (en) | 2016-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2012305212B2 (en) | Piperazine- substituted benzothiophene derivatives as antipsychotic agents | |
JP2014516072A (en) | Apixaban production method | |
US20120149735A1 (en) | 1,4-Dihydropyridine Derivatives and Their Uses | |
WO2014163622A1 (en) | Multifunctional quinoline derivatives as anti-neurodegenerative agents | |
WO2019120210A1 (en) | Benzofuran, coumestans derivatives, preparation method and use thereof | |
WO2016074532A1 (en) | Method for preparing alectinib | |
WO2014135096A1 (en) | Ivacaftor preparation method and intermediate thereof | |
JP6371741B2 (en) | Synthesis and anticancer activity of aryl and heteroaryl-quinoline derivatives | |
JP2010215620A (en) | NEW METHOD, PURIFICATION AND CRYSTALLIZATION OF 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-DIMORPHOLIN-4-YL-1,3,5-TRIAZIN-2-YL)PHENYL]UREA WHICH IS PI3K/mTOR INHIBITOR | |
JPH0592957A (en) | 2-substituted quinolines, preparation thereof, and use thereof in medicine | |
JP7256130B2 (en) | Guanidine derivative | |
CN113366010A (en) | Terpenoid derivative and application thereof | |
CN109280032B (en) | Pyridazinone mother nucleus structure histone deacetylase inhibitor and preparation method and application thereof | |
CN105924362A (en) | Aromatic cyclopropyl amine compound, pharmaceutically acceptable salts thereof, and preparation method and application thereof | |
MX2014014895A (en) | Bendamustine derivatives and related compounds, and medical use thereof cancer therapy. | |
JP2022515070A (en) | Amide derivative impurities and their use | |
CN108864132B (en) | Oridonin derivatives, and preparation method and application thereof | |
US9302992B2 (en) | Multifunctional quinoline derivatives as anti-neurodegenerative agents | |
CA3163243A1 (en) | Sstr5 antagonists | |
WO2014081025A1 (en) | Novel crystal form of 3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-n-(2-hydroxyethoxy)-5-(3-oxo-[1,2]oxazinan-2-ylmethyl)benzamide | |
WO2022191092A1 (en) | Quinoline compound, hnmt inhibitor, and agent for preventing/treating adhd, narcolepsy, or alzheimer's disease | |
WO2024061300A1 (en) | Inhibitors of trex1 and uses thereof | |
JP2024511617A (en) | Novel indoleamine-2,3-dioxygenase inhibitor, method for producing the same, and pharmaceutical composition containing the same | |
KR101568484B1 (en) | benzotellurophene derivative | |
CN108864113A (en) | A kind of bis- target spot inhibitor of MDM2-HDAC, pharmaceutical composition and its preparation and use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201380075030.2 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13881032 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013881032 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 241295 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 20157026392 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2013385618 Country of ref document: AU Date of ref document: 20130402 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2016506301 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2015137621 Country of ref document: RU Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112015024472 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112015024472 Country of ref document: BR Kind code of ref document: A2 Effective date: 20150923 |